Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Capital Expenditures (2020 - 2024)

Immuneering has reported Capital Expenditures over the past 5 years, most recently at $9356.0 for Q4 2024.

  • Quarterly results put Capital Expenditures at $9356.0 for Q4 2024, down 94.53% from a year ago — trailing twelve months through Dec 2024 was $84875.0 (down 75.24% YoY), and the annual figure for FY2025 was $142226.0, up 67.57%.
  • Capital Expenditures for Q4 2024 was $9356.0 at Immuneering, up from $5268.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for IMRX hit a ceiling of $393134.0 in Q3 2022 and a floor of $5268.0 in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $35125.5 (2024), compared with a mean of $70808.4.
  • Biggest five-year swings in Capital Expenditures: soared 3364.96% in 2022 and later plummeted 94.53% in 2024.
  • Immuneering's Capital Expenditures stood at $38058.0 in 2020, then plummeted by 65.7% to $13052.0 in 2021, then surged by 430.97% to $69302.0 in 2022, then surged by 146.63% to $170918.0 in 2023, then plummeted by 94.53% to $9356.0 in 2024.
  • The last three reported values for Capital Expenditures were $9356.0 (Q4 2024), $5268.0 (Q3 2024), and $32773.0 (Q2 2024) per Business Quant data.